阿德福韦酯联合苦参素胶囊治疗慢性乙型肝炎疗效观察及对乙型肝炎病毒脱氧核糖核酸的影响

Therapeutic effects of adefovir dipivoxil combined with matrine capsules on patients with chronic hepatitis B and its influence on HBV-DNA

目的:研究阿德福韦酯联合苦参素胶囊治疗慢性乙型肝炎的疗效及对乙肝病毒DNA的影响。方法:将86例慢性乙型肝炎患者纳入研究对象,随机分为给予阿德福韦酯联合苦参素胶囊治疗的观察组和单独给予阿德福韦酯治疗的对照组,观察肝功能指标、肝纤维化指标及不良反应例数。结果:观察组患者的ALT(37.8±7.2)U·L-1、AST水平(35.5±6.9)U·L-1、HBV-DNA拷贝数(3.1±0.9)×104及耐药例数(3)、HA(61.3±11.4)ng·ml-1、LN(118.9±13.7)ng·ml-1、ⅣC(74.3±12.8)ng·ml-1、PⅢNP(11.4±2.8)ng·ml-1及不良反应例数(7)明显低于对照组,HBV-DNA转阴例数(42)明显高于对照组(P<0.05)。结论:阿德福韦酯联合苦参素胶囊治疗能够改善肝功能、减少HBV-DNA拷贝数,且安全性理想。

OBJECTIVE To study the therapeutic effects of adefovir dipivoxil combined with matrine capsules on patients with chronic hepatitis B and its influence on HBV-DNA. METHODS 86 cases patients with chronic hepatitis B were divided into observation group （given adefovir dipivoxil combined with matrine capsules treatment） and control group （given adefovir dip- ivoxil）. The liver function index,hepatic fibrosis indexes and adverse reactions were observed. RESULTS ALT （37. 8 ± 7. 2）U. L- l and AST level （35.5 ± 6. 9）U. L^-1, HBV-DNA copy number （3.1 ± 0. 9） × 10^4 , resistance cases （3）, HA （61.3 ± 11.4）ng. ml 1 , LN （118. 9±13.7）ng. ml^-1, IV C （74. 3±12.8）ng. ml^-1 , P III NP （11.4 ± 2. 8）ng. ml i and cases of adverse reactions （7） in observation group were significantly lower than those in control group HBV-DNA negative cases （42）was significantly higher than that of the control group. （}ONCLUSION Adefovir dipivoxil combined with matrine capsules can improve liver function, reduce HBV DNA copy number and have good safety.